Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Charles Daley to Anti-Bacterial Agents

This is a "connection" page, showing publications Charles Daley has written about Anti-Bacterial Agents.

 
Connection Strength
  
 
 
4.719
  
  1. Griffith DE, Daley CL. Treatment of Mycobacterium abscessus Pulmonary Disease. Chest. 2022 01; 161(1):64-75.
    View in: PubMed
    Score: 0.413
  2. Daley CL, Winthrop KL. Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management. J Infect Dis. 2020 08 20; 222(Suppl 4):S199-S211.
    View in: PubMed
    Score: 0.387
  3. Koh WJ, Jeong BH, Jeon K, Park HY, Kim SY, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL. Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother. 2015 Aug; 59(8):4994-6.
    View in: PubMed
    Score: 0.269
  4. Daley CL, Glassroth J. Treatment of pulmonary nontuberculous mycobacterial infections: many questions remain. Ann Am Thorac Soc. 2014 Jan; 11(1):96-7.
    View in: PubMed
    Score: 0.244
  5. van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother. 2012 Dec; 56(12):6324-7.
    View in: PubMed
    Score: 0.224
  6. Daley CL. Nontuberculous mycobacterial disease in transplant recipients: early diagnosis and treatment. Curr Opin Organ Transplant. 2009 Dec; 14(6):619-24.
    View in: PubMed
    Score: 0.184
  7. Kasperbauer SH, Daley CL. Diagnosis and treatment of infections due to Mycobacterium avium complex. Semin Respir Crit Care Med. 2008 Oct; 29(5):569-76.
    View in: PubMed
    Score: 0.169
  8. Nguyen MH, Daley CL. Treatment of Mycobacterium avium Complex Pulmonary Disease: When Should I Treat and What Therapy Should I Start? Clin Chest Med. 2023 12; 44(4):771-783.
    View in: PubMed
    Score: 0.119
  9. Kang N, Jeon K, Kim H, Kwon OJ, Huh HJ, Lee NY, Daley CL, Koh WJ, Jhun BW. Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease. Chest. 2021 08; 160(2):436-445.
    View in: PubMed
    Score: 0.100
  10. Flume PA, Griffith DE, Chalmers JD, Daley CL, Olivier K, O'Donnell A, Aksamit T, Kasperbauer S, Leitman A, Winthrop KL. Development of Drugs for Nontuberculous Mycobacterial Disease: Clinicians' Interpretation of a US Food and Drug Administration Workshop. Chest. 2021 02; 159(2):537-543.
    View in: PubMed
    Score: 0.097
  11. Huh HJ, Kim SY, Shim HJ, Kim DH, Yoo IY, Kang OK, Ki CS, Shin SY, Jhun BW, Shin SJ, Daley CL, Koh WJ, Lee NY. GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance. J Clin Microbiol. 2019 08; 57(8).
    View in: PubMed
    Score: 0.090
  12. Kim DH, Jhun BW, Moon SM, Kim SY, Jeon K, Kwon OJ, Huh HJ, Lee NY, Shin SJ, Daley CL, Koh WJ. In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. Antimicrob Agents Chemother. 2019 08; 63(8).
    View in: PubMed
    Score: 0.090
  13. Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R, Hasegawa N, Jhun BW, Koh WJ, Namkoong H, Park J, Thomson R, van Ingen J, Zweijpfenning SMH, Yim JJ. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J. 2019 07; 54(1).
    View in: PubMed
    Score: 0.090
  14. Kwon YS, Daley CL, Koh WJ. Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches. Expert Rev Respir Med. 2019 09; 13(9):851-861.
    View in: PubMed
    Score: 0.090
  15. Kim SY, Moon SM, Jhun BW, Kwon OJ, Huh HJ, Lee NY, Lee SH, Shin SJ, Kasperbauer SH, Huitt GA, Daley CL, Koh WJ. Species Distribution and Macrolide Susceptibility of Mycobacterium fortuitum Complex Clinical Isolates. Antimicrob Agents Chemother. 2019 06; 63(6).
    View in: PubMed
    Score: 0.089
  16. Moon SM, Jhun BW, Baek SY, Kim S, Jeon K, Ko RE, Shin SH, Lee H, Kwon OJ, Huh HJ, Ki CS, Lee NY, Chung MJ, Lee KS, Shin SJ, Daley CL, Koh WJ. Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. Respir Med. 2019 05; 151:1-7.
    View in: PubMed
    Score: 0.088
  17. Kasperbauer SH, Daley CL. Mycobacterium chimaera Infections Related to the Heater-Cooler Unit Outbreak: A Guide to Diagnosis and Management. Clin Infect Dis. 2019 03 19; 68(7):1244-1250.
    View in: PubMed
    Score: 0.088
  18. Kim SY, Jhun BW, Moon SM, Jeon K, Kwon OJ, Huh HJ, Lee NY, Shin SJ, Daley CL, Koh WJ. Genetic mutations in linezolid-resistant Mycobacterium avium complex and Mycobacterium abscessus clinical isolates. Diagn Microbiol Infect Dis. 2019 May; 94(1):38-40.
    View in: PubMed
    Score: 0.086
  19. Jhun BW, Kim SY, Moon SM, Jeon K, Kwon OJ, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL, Koh WJ. Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease. Am J Respir Crit Care Med. 2018 11 15; 198(10):1322-1330.
    View in: PubMed
    Score: 0.086
  20. Jhun BW, Yang B, Moon SM, Lee H, Park HY, Jeon K, Kwon OJ, Ahn J, Moon IJ, Shin SJ, Daley CL, Koh WJ. Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease. Antimicrob Agents Chemother. 2018 07; 62(7).
    View in: PubMed
    Score: 0.083
  21. Jhun BW, Moon SM, Kim SY, Park HY, Jeon K, Kwon OJ, Huh HJ, Ki CS, Lee NY, Chung MJ, Lee KS, Shin SJ, Daley CL, Koh WJ. Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother. 2018 02; 62(2).
    View in: PubMed
    Score: 0.081
  22. Choi H, Jhun BW, Kim SY, Kim DH, Lee H, Jeon K, Kwon OJ, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL, Koh WJ. Treatment outcomes of macrolide-susceptible Mycobacterium abscessus lung disease. Diagn Microbiol Infect Dis. 2018 Apr; 90(4):293-295.
    View in: PubMed
    Score: 0.080
  23. Koh WJ, Moon SM, Kim SY, Woo MA, Kim S, Jhun BW, Park HY, Jeon K, Huh HJ, Ki CS, Lee NY, Chung MJ, Lee KS, Shin SJ, Daley CL, Kim H, Kwon OJ. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J. 2017 09; 50(3).
    View in: PubMed
    Score: 0.079
  24. Choi H, Kim SY, Kim DH, Huh HJ, Ki CS, Lee NY, Lee SH, Shin S, Shin SJ, Daley CL, Koh WJ. Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease. Antimicrob Agents Chemother. 2017 10; 61(10).
    View in: PubMed
    Score: 0.079
  25. Daley CL. Mycobacterium avium Complex Disease. Microbiol Spectr. 2017 04; 5(2).
    View in: PubMed
    Score: 0.076
  26. Olivier KN, Griffith DE, Eagle G, McGinnis JP, Micioni L, Liu K, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume PA, Dorgan D, Salathe M, Brown-Elliott BA, Gupta R, Wallace RJ. Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. Am J Respir Crit Care Med. 2017 03 15; 195(6):814-823.
    View in: PubMed
    Score: 0.076
  27. Choi H, Kim SY, Lee H, Jhun BW, Park HY, Jeon K, Kim DH, Huh HJ, Ki CS, Lee NY, Lee SH, Shin SJ, Daley CL, Koh WJ. Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease. Antimicrob Agents Chemother. 2017 02; 61(2).
    View in: PubMed
    Score: 0.076
  28. Koh WJ, Jeong BH, Kim SY, Jeon K, Park KU, Jhun BW, Lee H, Park HY, Kim DH, Huh HJ, Ki CS, Lee NY, Kim HK, Choi YS, Kim J, Lee SH, Kim CK, Shin SJ, Daley CL, Kim H, Kwon OJ. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. Clin Infect Dis. 2017 Feb 01; 64(3):309-316.
    View in: PubMed
    Score: 0.074
  29. Moon SM, Park HY, Kim SY, Jhun BW, Lee H, Jeon K, Kim DH, Huh HJ, Ki CS, Lee NY, Kim HK, Choi YS, Kim J, Lee SH, Kim CK, Shin SJ, Daley CL, Koh WJ. Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother. 2016 11; 60(11):6758-6765.
    View in: PubMed
    Score: 0.074
  30. Jeong BH, Jeon K, Park HY, Moon SM, Kim SY, Lee SY, Shin SJ, Daley CL, Koh WJ. Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother. 2016 10; 60(10):6076-83.
    View in: PubMed
    Score: 0.074
  31. Henkle E, Aksamit T, Barker A, Daley CL, Griffith D, Leitman P, Leitman A, Malanga E, Marras TK, Olivier KN, Prevots DR, Prieto D, Quittner AL, Skach W, Walsh JW, Winthrop KL. Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report. Ann Am Thorac Soc. 2016 09; 13(9):S379-84.
    View in: PubMed
    Score: 0.073
  32. Park HY, Jeong BH, Chon HR, Jeon K, Daley CL, Koh WJ. Lung Function Decline According to Clinical Course in Nontuberculous Mycobacterial Lung Disease. Chest. 2016 Dec; 150(6):1222-1232.
    View in: PubMed
    Score: 0.072
  33. Mase SR, Jereb JA, Gonzalez D, Martin F, Daley CL, Fred D, Loeffler AM, Menon LR, Bamrah Morris S, Brostrom R, Chorba T, Peloquin CA. Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands. Pediatr Infect Dis J. 2016 Apr; 35(4):414-21.
    View in: PubMed
    Score: 0.071
  34. Czaja CA, Levin AR, Cox CW, Vargas D, Daley CL, Cott GR. Improvement in Quality of Life after Therapy for Mycobacterium abscessus Group Lung Infection. A Prospective Cohort Study. Ann Am Thorac Soc. 2016 Jan; 13(1):40-8.
    View in: PubMed
    Score: 0.070
  35. Winthrop KL, Ku JH, Marras TK, Griffith DE, Daley CL, Olivier KN, Aksamit TR, Varley CD, Mackey K, Prevots DR. The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. Eur Respir J. 2015 Apr; 45(4):1177-9.
    View in: PubMed
    Score: 0.066
  36. Jeong BH, Jeon K, Park HY, Kim SY, Lee KS, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL, Koh WJ. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015 Jan 01; 191(1):96-103.
    View in: PubMed
    Score: 0.065
  37. Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis. 2011 Mar 01; 52(5):565-71.
    View in: PubMed
    Score: 0.050
  38. Marras TK, Morris A, Gonzalez LC, Daley CL. Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus. Am J Respir Crit Care Med. 2004 Oct 01; 170(7):793-8.
    View in: PubMed
    Score: 0.032
  39. Burgos M, DeRiemer K, Small PM, Hopewell PC, Daley CL. Effect of drug resistance on the generation of secondary cases of tuberculosis. J Infect Dis. 2003 Dec 15; 188(12):1878-84.
    View in: PubMed
    Score: 0.030
  40. Calado Nogueira de Moura V, Nguyen MH, Hunkins JJ, Daley CL, Khare R. In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022. J Antimicrob Chemother. 2023 12 01; 78(12):2849-2858.
    View in: PubMed
    Score: 0.030
  41. Hunkins JJ, de-Moura VC, Eddy JJ, Daley CL, Khare R. In vitro susceptibility patterns for rapidly growing nontuberculous mycobacteria in the United States. Diagn Microbiol Infect Dis. 2023 Mar; 105(3):115882.
    View in: PubMed
    Score: 0.028
  42. Nick JA, Dedrick RM, Gray AL, Vladar EK, Smith BE, Freeman KG, Malcolm KC, Epperson LE, Hasan NA, Hendrix J, Callahan K, Walton K, Vestal B, Wheeler E, Rysavy NM, Poch K, Caceres S, Lovell VK, Hisert KB, de Moura VC, Chatterjee D, De P, Weakly N, Martiniano SL, Lynch DA, Daley CL, Strong M, Jia F, Hatfull GF, Davidson RM. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell. 2022 05 26; 185(11):1860-1874.e12.
    View in: PubMed
    Score: 0.027
  43. Dousa KM, Nguyen DC, Kurz SG, Taracila MA, Bethel CR, Schinabeck W, Kreiswirth BN, Brown ST, Boom WH, Hotchkiss RS, Remy KE, Jacono FJ, Daley CL, Holland SM, Miller AA, Bonomo RA. Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane ?-Lactamase Inhibitor To Augment ?-Lactam Action. mBio. 2022 02 22; 13(1):e0352921.
    View in: PubMed
    Score: 0.027
  44. Davidson RM, Hasan NA, Epperson LE, Benoit JB, Kammlade SM, Levin AR, Calado de Moura V, Hunkins J, Weakly N, Beagle S, Sagel SD, Martiniano SL, Salfinger M, Daley CL, Nick JA, Strong M. Population Genomics of Mycobacterium abscessus from U.S. Cystic Fibrosis Care Centers. Ann Am Thorac Soc. 2021 12; 18(12):1960-1969.
    View in: PubMed
    Score: 0.026
  45. Nguyen DC, Dousa KM, Kurz SG, Brown ST, Drusano G, Holland SM, Kreiswirth BN, Boom WH, Daley CL, Bonomo RA. "One-Two Punch": Synergistic ?-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes. Clin Infect Dis. 2021 10 20; 73(8):1532-1536.
    View in: PubMed
    Score: 0.026
  46. Marras SAE, Chen L, Shashkina E, Davidson RM, Strong M, Daley CL, Kreiswirth BN. A Molecular-Beacon-Based Multiplex Real-Time PCR Assay To Distinguish Mycobacterium abscessus Subspecies and Determine Macrolide Susceptibility. J Clin Microbiol. 2021 07 19; 59(8):e0045521.
    View in: PubMed
    Score: 0.026
  47. Martiniano SL, Wagner BD, Brennan L, Wempe MF, Anderson PL, Daley CL, Anthony M, Nick JA, Sagel SD. Pharmacokinetics of oral antimycobacterials and dosing guidance for Mycobacterium avium complex treatment in cystic fibrosis. J Cyst Fibros. 2021 09; 20(5):772-778.
    View in: PubMed
    Score: 0.025
  48. Dousa KM, Kurz SG, Taracila MA, Bonfield T, Bethel CR, Barnes MD, Selvaraju S, Abdelhamed AM, Kreiswirth BN, Boom WH, Kasperbauer SH, Daley CL, Bonomo RA. Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors. Antimicrob Agents Chemother. 2020 07 22; 64(8).
    View in: PubMed
    Score: 0.024
  49. Moon SM, Jhun BW, Daley CL, Koh WJ. Unresolved issues in treatment outcome definitions for nontuberculous mycobacterial pulmonary disease. Eur Respir J. 2019 05; 53(5).
    View in: PubMed
    Score: 0.022
  50. Daniel-Wayman S, Abate G, Barber DL, Bermudez LE, Coler RN, Cynamon MH, Daley CL, Davidson RM, Dick T, Floto RA, Henkle E, Holland SM, Jackson M, Lee RE, Nuermberger EL, Olivier KN, Ordway DJ, Prevots DR, Sacchettini JC, Salfinger M, Sassetti CM, Sizemore CF, Winthrop KL, Zelazny AM. Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research. Am J Respir Crit Care Med. 2019 04 15; 199(8):947-951.
    View in: PubMed
    Score: 0.022
  51. Koh WJ, Jeong BH, Jeon K, Kim SY, Park KU, Park HY, Huh HJ, Ki CS, Lee NY, Lee SH, Kim CK, Daley CL, Shin SJ, Kim H, Kwon OJ. Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of Mycobacterium massiliense Lung Disease. Chest. 2016 Dec; 150(6):1211-1221.
    View in: PubMed
    Score: 0.018
  52. Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016 Jan; 71 Suppl 1:i1-22.
    View in: PubMed
    Score: 0.018
  53. Choi GE, Shin SJ, Won CJ, Min KN, Oh T, Hahn MY, Lee K, Lee SH, Daley CL, Kim S, Jeong BH, Jeon K, Koh WJ. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med. 2012 Nov 01; 186(9):917-25.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)